Clinical Trial Update: A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of CNTO 328 (siltuximab) in patients with metastatic hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CNTO 328

Snippet

Sponsor: Centocor, Inc. | Conditions: Prostatic Neoplasms | Phase 1 | Status: COMPLETED